Institution
Cochin University of Science and Technology
Education•Kochi, Kerala, India•
About: Cochin University of Science and Technology is a education organization based out in Kochi, Kerala, India. It is known for research contribution in the topics: Thin film & Natural rubber. The organization has 5382 authors who have published 7690 publications receiving 103827 citations. The organization is also known as: CUSAT & Cochin University.
Topics: Thin film, Natural rubber, Microstrip antenna, Dielectric, Catalysis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, six new copper(II) complexes of 2-benzoylpyridine N(4)-cyclohexyl thiosemicarbazone (HL) have been synthesized and characterized by different physicochemical techniques like molar conductivity measurements, magnetic studies and electronic, infrared and EPR spectral studies.
111 citations
••
TL;DR: In this paper, a new group of compounds with composition (Ba5 5 − x Sr x )Nb 4 O 15, having high permittivity and low loss have been prepared and characterised in the microwave frequency region.
111 citations
••
TL;DR: Impact of acute salinity stress on the immunological and physiological response of Penaeus monodon to white spot syndrome virus (WSSV) infection was analysed.
111 citations
••
TL;DR: The spectral studies and structure of a ternary complex of copper(II) with 2-hydroxyacetophenone 3-hexamethyliminylthiosemicarbazonate (L(2-)) and 1,10-phenanthroline (phen) are reported.
111 citations
••
TL;DR: This trial is in favour of using adalimumab in patients with early onset, chronic anterior uveitis, which is in most cases associated with JIA, in case of inadequate response to topical therapy and MTX.
Abstract: Objectives To assess the efficacy and safety of adalimumab on uveitis in patients with early onset, chronic, juvenile idiopathic arthritis (JIA)-associated or idiopathic anterior uveitis and an inadequate response to topical steroids and methotrexate (MTX). Methods Patients aged 4 years or more with ocular inflammation quantified by laser flare photometry (LFP) ≥30 photon units/ms were double-blindly randomised (1:1) to 2 groups, one treated with placebo and one with adalimumab subcutaneously at a dose of 24 mg/m 2 in patients aged Results At M2, among 31 patients included in intention-to-treat analysis, there were 9/16 responders on adalimumab and 3/15 on placebo (P=0.038, Χ 2 test; relative risk=2.81, 95% CI 0.94 to 8.45; risk difference: 36.3%, 95% CI 2.1 to 60.6); there was no significant difference using the Standardised Uveitis Nomenclature classification criteria of improvement. Thirty patients continued the trial after M2 and received adalimumab (open-label phase), 29 reached M12. There were seven serious adverse events none related to study treatment. Conclusions This trial is in favour of using adalimumab in patients with early onset, chronic anterior uveitis, which is in most cases associated with JIA, in case of inadequate response to topical therapy and MTX. LFP could be a valuable tool to assess early treatment efficacy. Trial registration number NCT01385826.
109 citations
Authors
Showing all 5433 results
Name | H-index | Papers | Citations |
---|---|---|---|
Pulickel M. Ajayan | 176 | 1223 | 136241 |
Maxime Dougados | 134 | 1054 | 69979 |
Sabu Thomas | 102 | 1554 | 51366 |
Philippe Ravaud | 101 | 618 | 41409 |
David P. Salmon | 99 | 419 | 43935 |
Jérôme Bertherat | 85 | 438 | 24794 |
Luc Mouthon | 84 | 564 | 26238 |
Xavier Bertagna | 74 | 285 | 18738 |
Alfred Mahr | 73 | 229 | 22581 |
Nicolas Roche | 72 | 629 | 22845 |
Charles Chapron | 71 | 378 | 18048 |
Benoit Terris | 61 | 234 | 13353 |
François Goffinet | 60 | 532 | 14433 |
Xavier Puéchal | 60 | 316 | 13240 |
Pascal Laugier | 58 | 482 | 10518 |